Search - tctmd.com

Displaying 1 - 20 of 50

Sort: Relevancy | Date

News Daily News

Hospital Mortality for Patients With A-fib Higher in Rural Areas

Todd Neale

December 11, 2017

News Daily News

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

Michael O'Riordan

December 04, 2017

News Daily News

A Visit With a Cardiologist May Improve A-fib Outcomes

Todd Neale

November 28, 2017

News Conference News AHA 2017

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Michael O'Riordan

November 17, 2017

News Conference News AHA 2017

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Todd Neale

November 14, 2017

News Conference News AHA 2017

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Yael L. Maxwell

November 13, 2017

News Conference News TCT 2017

Early Pilot Study Results Show Symptom Improvement With TMVR

Michael O'Riordan

November 07, 2017

News Daily News

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Michael O'Riordan

October 19, 2017

News Daily News

Blood in Urine Carries Consequences for Patients on Antithrombotics

Yael L. Maxwell

October 09, 2017

News Daily News

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

L.A. McKeown

October 09, 2017

News Daily News

CTA Reduces MI Compared With Functional Stress Testing, but at a Cost

Michael O'Riordan

October 05, 2017

News Daily News

Generic ARBs Linked to Increased Adverse Events

Michael O'Riordan

October 04, 2017

News Industry News

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

October 02, 2017

News Daily News

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Michael O'Riordan

September 27, 2017

News Daily News

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Michael O'Riordan

September 21, 2017

News Daily News

Frail Patients Benefit From MitraClip, With Gains in Function and Quality of Life

Michael O'Riordan

September 18, 2017

News Industry News

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

September 15, 2017

News Conference News ESC 2017

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Michael O'Riordan

August 27, 2017

News Daily News

Readmissions After Acute MI Not Only Confined to the Elderly

Yael L. Maxwell

August 09, 2017

News Daily News

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Michael O'Riordan

August 08, 2017

Advertisement

Hospital Mortality for Patients With A-fib Higher in Rural Areas

It’s Official: Evolocumab Gains Claim for CVD Event Reduction

A Visit With a Cardiologist May Improve A-fib Outcomes

Diabetes Drugs Show Benefit in PAD, but Only Mixed Results in Primary Prevention of CV Events

Low-Dose Rivaroxaban Plus Aspirin Lowers Some Costs in COMPASS, but Full Economic Impact Unclear

Two FOURIER Subgroup Analyses Show Added Benefit of Evolocumab in Those With PAD, Prior MI

Early Pilot Study Results Show Symptom Improvement With TMVR

Evolocumab ‘Abjectly Fails’ Another Financial Stress Test

Blood in Urine Carries Consequences for Patients on Antithrombotics

Same-Day Discharge After PAD Procedures Safe in Elderly Patients

CTA Reduces MI Compared With Functional Stress Testing, but at a Cost

Generic ARBs Linked to Increased Adverse Events

Geisinger and Boehringer Ingelheim collaborate to create a predictive model to help improve health outcomes for people with type 2 diabetes at greatest risk of serious long-term complications, including cardiovascular death

Paravalvular Regurgitation With Sapien 3 Rare but Still Can Be Deadly

Study Questions Incremental Benefit of Beta-Blockers After Acute MI

Frail Patients Benefit From MitraClip, With Gains in Function and Quality of Life

New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes

CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events

Readmissions After Acute MI Not Only Confined to the Elderly

Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content